May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab Treatment of Retinal Pigment Epithelial Detachment Due to Age-Related Macular Degeneration
Author Affiliations & Notes
  • R. Margolis
    Ophthalmology, Cole Eye Institute, Cleveland, Ohio
  • R. P. Singh
    Ophthalmology, Cole Eye Institute, Cleveland, Ohio
  • P. K. Kaiser
    Ophthalmology, Cole Eye Institute, Cleveland, Ohio
  • Footnotes
    Commercial Relationships R. Margolis, None; R.P. Singh, None; P.K. Kaiser, Genentech, F.
  • Footnotes
    Support Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4560. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Margolis, R. P. Singh, P. K. Kaiser; Intravitreal Bevacizumab Treatment of Retinal Pigment Epithelial Detachment Due to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4560.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To evaluate the effect of intravitreal bevacizumab treatment on pigment epithelial detachment (PED) due to neovascular age-related macular degeneration (AMD), and to identify prognostic factors for regression of PED and improvement in visual acuity.

Methods:: Twenty-one patients (21 eyes) with active CNV from neovascular AMD with PED were identified from a retrospective chart review from November, 2005 to July, 2006. A cohort of 25 AMD patients with CNV without PED was chosen randomly for comparison of change in retinal thickness in response to treatment. All patients received 3 intravitreal injections of bevacizumab (1.25 mg) during a 3 month period. Patients were examined at baseline and after each treatment using optical coherence tomography (OCT). Maximal PED height and area were analyzed using Image J software. Minimal retinal thickness was measured by calipers using the OCT software. Changes in PED dimensions were correlated with changes in retinal thickness and visual acuity.

Results:: Mean baseline visual acuity in eyes with PED was 20/143, and the mean visual acuity of non-PED eyes was 20/168. Baseline mean minimal retinal thickness in PED eyes was 901 microns, and baseline mean minimal retinal thickness in non-PED eyes was 577 microns. The average baseline PED area was 400.9 microns. PED eyes experienced a decline of 25.4% in total retinal thickness after one injection, and a total decline of 26.4% after three injections. In comparison, non-PED eyes experienced a decline of 26.9% after one injection and 33.5% after three injections. PED area decreased by 32.3% after one injection, and by 35.5% after three injections. After three treatments, 83% of eyes retained a PED. Visual acuity after 3 treatments was 20/149 in PED eyes and 20/146 in non-PED eyes. Initial PED size was correlated to poorer anatomical and visual response.

Conclusions:: Intravitreal bevacizumab treatment was associated with a modest decrease in PED dimensions in patients with neovascular AMD. In a majority of patients, PED persisted despite repeated treatments with intravitreal bevacizumab. Initial PED size was found to be a negative predictive factor for treatment response and visual outcome.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.